Adverse Effect of Radiation Therapy Clinical Trial
Official title:
Circulating Tumor Cell Genome in Peripheral Blood From Hepatocellular Carcinoma Patients Under Radiotherapy
Hepatocellular carcinoma (HCC) is a common cause of cancer mortality in Asia. Most patients
were presented with advanced disease. Percutaneous ethanol injection, radiofrequency
ablation, and transcatheter arterial chemoembolization (TACE) are not considered as a
curative treatment and have achieved very limited success in eradicating large HCC or tumors
causing portal vein thrombosis. With the development of novel radiotherapy (RT) technique,
RT can be safely given to patients with larger tumor or portal vein thrombosis. However, RT
could achieve a tumor response rate of approximately 50 %. Currently, there was a paucity of
studies regarding a quantitative biomarker to predict tumor response or forecast the outcome
in advance. To optimize the therapeutic index, there is a need to seek effective biomarkers
for personal medicine because pretreatment AFP is not always useful as a surrogate marker in
some of the patients.
The present study is to investigate whether circulating tumor cell genome in peripheral
blood can be used to predict RT response in HCC. We will use the blood sample from patients
with locally advanced HCC receiving RT. By using next generation sequencing, We are going to
explore the quantity and quality changes of DNAs and RNAs in the patient's serum or plasma.
By this way, genomic expression in peripheral blood may play a key role in determining the
optimal therapeutic strategies for HCC patients by predicting tumor response to RT.
Patients with hepatocellular carcinoma requiring radiotherapy ;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02586727 -
Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy
|
Phase 2 | |
| Recruiting |
NCT02052102 -
Study to See Whether Breath-Hold Techniques During RT Are Effective in Helping to Improve Sparing of the Heart
|
Phase 2 | |
| Unknown status |
NCT01863420 -
The Effect of Bone Marrow-sparing Intensity-Modulated Radiotherapy to GI Cancer
|
Phase 2 | |
| Completed |
NCT02922244 -
Effects of Herbal Products on Reduction of Radiation-induced Dermatitis in Breast Cancer Patients
|
N/A | |
| Completed |
NCT02406183 -
Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma
|
Phase 1 | |
| Completed |
NCT01621880 -
Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT02114086 -
IORT-Boost-Study, Prospective Observational Study for Intraoperative Radiotherapy of the Breast as a Boost
|
||
| Completed |
NCT02142907 -
Evaluation of Two Boost Radiation Schedules in Post Lumpectomy Early Stage Carcinoma Breast
|
||
| Not yet recruiting |
NCT04127760 -
Efficacy of Postoperative Radiotherapy for Atypical Meningioma Without Venous Sinus Invasion After Gross-total Resection
|
N/A | |
| Recruiting |
NCT04553510 -
Treatment of Bevacizumab Followed by Steroid in RN
|
Phase 2 | |
| Completed |
NCT03359187 -
Prevention of Mucositis in Patients With Head and Neck Cancer Treated With Radiotherapy
|
N/A | |
| Completed |
NCT00780312 -
Physiotherapy Treatment for Patients Suffering From Head and Neck Cancer
|
Phase 2 |